COVID - 19
Conditions
Keywords
COVID-19, SARS-COV-2
Brief summary
Since the first reported case of the novel coronavirus (SARS-CoV-2) in humans at the end of 2019 in Wuhan, the virus had infected approximately 100 million individuals. One year later, coronavirus disease (COVID-19) was estimated to have affected nearly 30% of the global population, with a case fatality rate of approximately 2%. In the early stages of the pandemic, numerous questions emerged regarding this novel viral agent, including its pathogenic mechanisms, associated vulnerabilities, risk factors, and potential treatment strategies. A wide spectrum of clinical conditions-including chronic diseases, infectious agents, autoimmune disorders, and even genetic or post-therapeutic alterations-can trigger inflammatory syndromes in the human body. A central component of these processes is the dysregulation of cytokine signaling, which may provoke excessive immune cell activation, leading to a self-perpetuating inflammatory loop with potentially life-threatening consequences. Notably, both SARS-CoV-2 infection and elevated C-reactive protein (CRP) levels have been consistently observed during active disease states. Furthermore, vitamin E is well known as an antioxidant that prevents the peroxidation of lipid molecules, as ferroptosis. A well-established phenomenon is that lipid peroxidation levels are higher in COVID-19 patients, while antioxidant capacity is diminished. Therefore, the aim of this study is to evaluate CRP levels in COVID-19 patients administered high doses of vitamin E (alpha-tocopherol)-a lipid-soluble antioxidant-compared to those receiving a placebo.
Interventions
DRUGPatients were randomly assigned, under a double-blind design, α-Tocopherol group (n = 22)
α-Tocopherol (alpha-tocopherol)
Sponsors
Universidad Veracruzana
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Two randomized controlled trials were conducted to assess the association between vitamin E supplementation and C-reactive protein (CRP, mg/L) levels. A total of 56 patients were randomly assigned, under a double-blind design, to either the vitamin E group (n = 22) or the placebo group (n = 34). An additional 33 patients were excluded due to negative SARS-CoV-2 PCR results. Among those included in the study, 62% (34/55) were men, and 38% (21/55) were women. The intervention group received 800 IU of α-tocopherol and was compared to the placebo group to evaluate treatment-related changes in CRP levels. Statistical analysis was performed using Student's t-test with permutations, comparing dependent groups (treated vs. untreated) at baseline (day 0) and after one week of treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Both adult males and females with less than 80 yeas old in age with confirmed covid-19 infection was selected.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vitamin E reduce CRP levels in COVID-19 patients | Baseline (Day 0) and after 3 months of treatment. | Our findings suggest that vitamin E supplementation may significantly reduce CRP levels in COVID-19 patients |
Countries
Mexico
Outcome results
None listed